Rupixiao Tablets
Shop NowOverview
What is Rupixiao Tablets?
Rupixiao Tablets are a 15-herb proprietary Traditional Chinese Medicine (TCM) herbal formula primarily used for breast nodules, breast lumps, and early-stage mastitis.
Product Information
| Chinese name | 乳癖消片 |
|---|---|
| Pinyin | Ru Pi Xiao Pian |
| Brand | Good Nurse |
| China Drug Approval No. | Z21021823 |
| Dosage form | tablet |
| Traditional function | Softens and disperses masses, promotes circulation to resolve swelling, and clears heat and toxins. |
| Strength | 0.32 g per tablet |
| Individual package | 0.32 g × 100 tablets |
| Recommended use | Labeled for traditional phlegm-heat accumulation presentations of breast lumps or breast abscess, including breast lumps of varying number, size, shape or soft texture, or postpartum breast lumps with redness and pain; early mastitis or mammary hyperplasia with the stated presentation. |
| GTIN | 6902215000056 |
Main ingredients: Deer antler, Dandelion, Kelp, Trichosanthes root, Suberect Spatholobus Stem, Notoginseng, Red peony root, Sargassum, Rhaponticum root, Aucklandia root, Scrophularia root, Moutan bark, Prunella spike, Forsythia fruit, Safflower
Evidence at a Glance
A meta-analysis reported higher response rates and fewer reported adverse reactions for Ru-Pi-Xiao plus tamoxifen than tamoxifen alone, while a separate 80-person comparator study also evaluated Rupixiao. Trial-reporting and allocation limitations keep the evidence uncertain.
Use cautiously during pregnancy.
Uses
Common Uses
Rupixiao Tablets are used for a breast lump or concerns related to a breast abscess, early mastitis, or mammary hyperplasia.
Traditional & Labeled Uses
软坚散结，活血消痈，清热解毒
Softens and disperses masses, promotes circulation to resolve swelling, and clears heat and toxins
- Traditional phlegm-heat breast-lump presentations
- Traditional phlegm-heat breast-abscess presentations
- Early mastitis with the stated traditional presentation
- Mammary hyperplasia with the stated traditional presentation
A labeled traditional use is not proof that this medicine diagnoses, treats, or prevents every breast lump, mastitis episode, or breast cancer. New, persistent, enlarging, or otherwise concerning breast changes need appropriate clinical evaluation.
Understanding the TCM Perspective
Phlegm-heat accumulation is a Traditional Chinese Medicine pattern term. It is not a biomedical diagnosis and cannot determine whether a breast lump is benign, inflammatory, or malignant.
Related TCM Patterns
Rupixiao Tablets is classified as a prescription medicine in China. This Learn information is for educational purposes only. Always consult a healthcare provider before starting TCM treatments.
Safety
Pregnancy
The product information states that pregnant people should use this medicine cautiously. Seek advice from a clinician or pharmacist before use during pregnancy or when trying to conceive.
Allergy
Do not use if you are allergic to Rupixiao Tablets or any listed ingredient. Stop use and seek urgent help for swelling, wheezing, trouble breathing, or another severe allergic reaction.
Breastfeeding
Product-specific breastfeeding safety information was not identified in the reviewed sources. Consult a clinician or pharmacist before use while breastfeeding.
Younger Users
Product-specific pediatric safety and effectiveness information was not identified in the reviewed sources. Consult a clinician or pharmacist before use in children or adolescents.
Drug Interactions
The reviewed product information does not identify specific established interaction pairs. If you use tamoxifen, anticoagulants, hormonal treatment, or other medicines or herbal products, ask a clinician or pharmacist before combining them; do not change prescribed treatment without advice.
When to Seek Medical Advice
Seek prompt medical assessment for a new or persistent breast lump, nipple discharge, skin changes, fever, increasing redness or pain, or symptoms that do not improve. Do not delay investigation of a possible breast cancer or infection while self-treating.
Evidence
Human Clinical Evidence
Ru-Pi-Xiao plus tamoxifen: meta-analysis of randomized trials
The meta-analysis reported higher response rates and fewer reported adverse reactions for Ru-Pi-Xiao plus tamoxifen than tamoxifen alone.
Rupixiao compared with acupoint catgut embedding
Both groups improved from baseline; the acupoint-embedding group was reported as superior to the Rupixiao group.
Verification
PRODUCT IDENTITY
- Brand Name
- Good Nurse
- Chinese Name
- 好护士
- Manufacturer
- Liaoning Shangyao Good Nurse Pharmaceutical (Group) Co., Ltd.
- China drug approval number
- Z21021823
- Prescription status in China
- Prescription medicine.
These are Chinese product-registration details. They do not establish approval or availability in another country.
Verified by the AuthHerb Verification Team
- Brand relationship confirmed
- Manufacturer legal name confirmed
- Approval number confirmed
- Current packaging matched
- Registration holder / manufacturer checked
- Authenticity method checked
- Label/source evidence recorded
Ingredients
This product contains the following ingredients:
- Deer antler — 鹿茸
- Dandelion — 蒲公英
- Kelp — 昆布
- Trichosanthes root — 天花粉
- Suberect Spatholobus stem — 鸡血藤
- Notoginseng — 三七
- Red peony root — 赤芍
- Sargassum — 海藻
- Rhaponticum root — 漏芦
- Costus root — 木香
- Scrophularia root — 玄参
- Moutan bark — 牡丹皮
- Prunella spike — 夏枯草
- Forsythia fruit — 连翘
- Safflower — 红花
Official Label Dosage
Take 5–6 tablets by mouth 3 times daily for the 0.32 g sugar-coated-tablet presentation.
Follow the current package insert if its instructions differ.
Individual package: 0.32 g × 100 tablets
Missed Dose Information
No product-specific missed-dose instruction was identified.
Additional Directions
The reviewed exact-product information does not provide a treatment-course duration. Follow the current physical package and clinician or pharmacist advice.
This instruction applies to the verified 0.32 g-per-tablet-core, 100-tablet presentation. Other Rupixiao Tablet strengths have different labeled tablet counts per dose.
A purchase option’s quantity does not define how long you should take the medicine.
Frequently Asked Questions About Rupixiao Tablets
The label describes traditional phlegm-heat accumulation presentations of breast lumps or breast abscess, including early mastitis or mammary hyperplasia with the stated presentation. This is not a biomedical diagnosis.
No. A new, persistent, enlarging, or otherwise concerning breast change needs clinical assessment. Traditional-use wording does not rule out infection, benign disease, or cancer.
Human studies and a meta-analysis have evaluated Rupixiao or Ru-Pi-Xiao preparations for mammary-gland hyperplasia. Important trial-quality, preparation and applicability limitations mean the findings should be interpreted cautiously.
The reviewed product information states 5–6 tablets by mouth, 3 times daily. Follow the current physical package and professional advice.
The label advises caution during pregnancy, and product-specific breastfeeding data were not identified. Consult a clinician or pharmacist before use.
References
-
[1]Ru-Pi-Xiao plus tamoxifen: meta-analysis of randomized trials
Population: 27 trials involving 4,368 participants with mammary gland hyperplasia.
Indication: Mammary gland hyperplasia
Intervention: Ru-Pi-Xiao plus tamoxifen, or Ru-Pi-Xiao alone in some included comparisons.
Comparison: Tamoxifen alone.
Sample size: 4368
Duration: 27 trials
Reported findings
The meta-analysis reported higher response rates and fewer reported adverse reactions for Ru-Pi-Xiao plus tamoxifen than tamoxifen alone.
Interpretation
This meta-analysis provides the broadest human evidence set for named Ru-Pi-Xiao interventions in mammary gland hyperplasia.
Limitations
All included studies were from China; allocation concealment and blinding were not reported, dose reporting was incomplete, and combination results do not isolate Ru-Pi-Xiao.
Li HT, Liu HH, Yang YX, et al. Therapeutic Effects of a Traditional Chinese Medicine Formula Plus Tamoxifen vs. Tamoxifen for the Treatment of Mammary Gland Hyperplasia: A Meta-Analysis of Randomized Trials. Frontiers in Pharmacology. 2018;9:45. doi:10.3389/fphar.2018.00045. PMID:29456506.
Study type: meta_analysis
PMID: 29456506
-
[2]Rupixiao compared with acupoint catgut embedding
Population: 80 people with mammary gland hyperplasia.
Indication: Mammary gland hyperplasia
Intervention: Rupixiao by mouth, 3 tablets 3 times daily for 3 months.
Comparison: Acupoint catgut embedding every 15 days for 3 months.
Sample size: 80
Duration: 3 months
Reported findings
Both groups improved from baseline; the acupoint-embedding group was reported as superior to the Rupixiao group.
Interpretation
This study provides direct human comparator evidence for a named Rupixiao intervention.
Limitations
Allocation by visit-day parity was not robust concealed randomization, and the Rupixiao arm was not the superior group.
Zhou L, Lu X, Feng ZG, Shen XX, Wu JQ. Effect of acupoint-catgut-embedment on mammary gland hyperplasia. Acupuncture Research. 2011;36(1):52–56. doi:10.13702/j.1000-0607.2011.01.013. PMID:21585060.
Study type: randomized_controlled_trial
PMID: 21585060